Please assess the completion status of the following clinical trial:

Trial Title: Mirasol-Treated Platelets - (Pathogen Reduction Extended Storage Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female of age of 18 years or older.~* Have thrombocytopenia or expected to develop thrombocytopenia requiring at least 3 platelet transfusions.~* Woman of child bearing potential must have a negative serum or urine pregnancy test within 72 hours before randomization.~* Subjects must have signed and dated the Informed Consent Form before performing any protocol related procedure.~Exclusion Criteria:~* History of any hypersensitivity reaction to riboflavin or metabolites.~* History of refractoriness to platelet transfusions (defined as 2 successive CCI1hr\<5000) or presence of human leukocyte antigen (HLA) antibodies or positive lymphocytotoxicity or previously documented alloimmunization.~* Previous exposure to PRT-treated platelet concentrates.~* Active bleeding requiring one or more red cells concentrate transfusions (i.e. grade 3 or 4 bleeding according to the WHO bleeding assessment scale in Appendix 1).~* Exposure to an investigational product, within 30 days before randomization.~* Splenomegaly (presence of a palpable spleen whose border could be felt more than 4 cm below the costal margin) or splenectomy.~* History or diagnosis of Immune/Idiopathic Thrombocytopenic Purpura (ITP), Thrombotic Thrombocytopenia Purpura (TTP), or Haemolytic Uremic Syndrome (HUS).~* Use of prohibited medication (see section 5.5).~* Pregnant or lactating females.~* Any medical condition or treatment that would be expected to compromise the effectiveness of a platelet transfusion or that would interfere with an expected platelet count increment.~* Any other medical condition that would compromise the participation of the subject in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mirasol first, then Reference (Type: ACTIVE_COMPARATOR): This study arm will receive first a 2-4-day-old Mirasol-treated platelets transfusion and then a reference 2-4-day-old untreated platelets transfusion (Mirasol-Reference sequence).
- Reference first, then Mirasol (Type: ACTIVE_COMPARATOR): This study arm will receive first a reference 2-4-day-old untreated platelets transfusion and then a 2-4-day-old Mirasol-treated platelets transfusion (Reference-Mirasol sequence).

Based on this trial design, predict the completion outcome and termination type (if applicable).